Mongolia Diagnostic & IVD Device Register Teardown: 2024 LMMD Reset
A data-driven teardown of Mongolia's diagnostic and IVD register. Analyze the risk-class split, country-of-origin mix, top manufacturers, and 2024 LMMD regulatory reset.
Executive Summary
For medical device and in vitro diagnostic (IVD) manufacturers, entering the Central and East Asian markets requires navigating diverse, rapidly shifting regulatory landscapes. Mongolia, a landlocked nation of 3.4 million people situated between China and Russia, represents a small but growing market for clinical diagnostics. Historically, general medical devices did not require formal state registration, but the diagnostic and IVD sectors have long been governed by strict registry requirements under the Ministry of Health.
According to our comprehensive database analysis of the official MMDRA Druginfo registered diagnostic/IVD products register (snapshot dated July 2026), the register contains exactly 1,349 active product listings. Key findings from this quantitative teardown include:
- 100% Import Dependence: Every single registered diagnostic product is classified as an import (
Оношлуур (Импортын)). There is zero domestic diagnostic manufacturing represented on the register. - Country of Origin Concentration: The market is heavily dominated by Asian supply chains. China is the leading source country with 410 registered products (30.4%), followed by Japan with 194 (14.4%), Germany with 173 (12.8%), and South Korea with 132 (9.8%). Combined, the three major East Asian producers (China, Japan, and South Korea) hold 736 active registrations, representing 54.6% of the entire database.
- Manufacturer Concentration: While 93 unique manufacturers are represented on the register, supply is highly concentrated. The top five manufacturers hold 34.3% (463/1,349) of all registrations: Shenzhen New Industries (154), Biomerieux S.A. (92), BioSystems S.A. (78), Shenzhen YHLO Biotech (77), and Sysmex Corporation (62).
- Temporal Registration Cohorts: Registrations grew rapidly between 2021 and 2023, peaking at 360 new registrations in 2023 before dropping to 164 in 2024 as the regulatory system underwent a comprehensive legislative overhaul.
- Looming Renewal Wave: Because registrations are valid for exactly 5 years, the historical registration curve indicates a massive expiry wave. Over 70% of active diagnostic registrations will expire and require renewal in 2027 (496 listings) and 2028 (451 listings).
For foreign manufacturers, market access is further complicated by a sweeping regulatory transition. The passage of the revised Law on Medicines and Medical Devices (LMMD) in June 2024 (effective October 1, 2024) and the subsequent issuance of Minister of Health Order No. A/206 (May 26, 2025) have fully reset the registration pathway, requiring all submissions to be processed through the digital LICEMED portal and placing new compliance burdens on local importers and foreign developers.
Introduction to Mongolia's Healthcare System and IVD Market
Mongolia's healthcare system is structured around three primary levels of care: primary care (family health centers, soum health centers), secondary care (district hospitals, provincial/aimag general hospitals), and tertiary care (specialized national centers and university hospitals in Ulaanbaatar). The capital city, Ulaanbaatar, houses nearly half of the country's population and concentrates the vast majority of advanced clinical laboratories, specialized medical equipment, and private diagnostic clinics.
The public healthcare sector is funded primarily through the State Budget and the Health Insurance Fund (HIF), which reimburses clinical services and diagnostics. Procurement of medical devices and IVD reagents for public hospitals is conducted through open public tenders, which require all participating products to hold active registration certificates.
Because Mongolia has no domestic manufacturing capacity for in vitro diagnostics, the clinical laboratory market is entirely dependent on imports. The private sector is growing rapidly, with a proliferation of private laboratories, imaging centers, and specialized clinics catering to patients seeking faster turnaround times and premium testing panels. For foreign IVD manufacturers, this creates a dual market opportunity: public tender channels driven by cost-effectiveness and volume, and a private channel driven by technological premium, automation, and clinical utility.
The Legal Framework: The 2024 LMMD and MoH Order A/206 Reset
To understand the Mongolian market, regulatory professionals must discard pre-2024 regulatory assumptions. For many years, general medical devices did not require a formal pre-market registration, and customs clearance was managed via import licenses. This changed with the legislative overhaul of 2024:
1. The Revised Law on Medicines and Medical Devices (LMMD 2024)
Passed by the State Great Khural (Mongolian Parliament) on June 5, 2024, and entering into force on October 1, 2024, the revised LMMD established a modernized, comprehensive framework for both pharmaceuticals and medical technologies. The law explicitly:
- Divides medical products into medicines, medical equipment (hardware), and medical supplies (disposables, diagnostics, and IVDs).
- Mandates that all medical devices, regardless of risk class, must hold a valid state registration or marketing authorization before they can be imported, distributed, or used in clinical practice.
- Empowers the MMDRA (Authority for Health and Medical Device Regulation) under the Ministry of Health as the sole administrative body responsible for evaluating dossiers, managing the register, and inspecting distribution facilities.
2. Minister of Health Order No. A/206 (May 26, 2025)
To implement the registration mandates of the LMMD, the Minister of Health issued Order No. A/206 on May 26, 2025, which enacted Attachment 2: "Procedure for the Registration and Marketing Authorization of Medical Devices." This order:
- Repealed the previous 2019 registration procedures.
- Established a computerized filing workflow using the LICEMED (licemed.mohs.mn) information system.
- Introduced a strict desk-review methodology based on EU MDR/IVDR standards and GHTF (Global Harmonization Task Force) classification principles.
- Defined the dossier templates, translation compliance gates, and updated fee schedules.
3. Core Administrative Rules
- Authorized Representative (Local Title Holder): A foreign manufacturer cannot apply for registration directly. The applicant must be a Mongolian legal entity (LLC) holding a valid Import and Supply License for Medical Devices issued by the Ministry of Health. Foreign representative offices are not permitted to hold registration certificates.
- Validity Period: Standard state registration certificates are valid for exactly 5 years. A simplified, fast-track registration of 3 years may be granted under specific bilateral recognition agreements or emergency provisions.
- Fees: Under the current schedule, registration fees are structured by application type:
- Full evaluation (new diagnostic product): 500,000 to 3,000,000 MNT (approx. $150 to $900 USD, depending on complexity and laboratory validation requirements).
- Renewal / Re-registration: 250,000 to 1,500,000 MNT (approx. $75 to $450 USD).
- Administrative variations (change of manufacturer address, minor labeling updates): 100,000 to 500,000 MNT.
Quantitative Teardown of the MMDRA Diagnostic Register
Analyzing the MMDRA Druginfo register reveals the competitive landscape, geographic supply hubs, and manufacturer strategies.
1. Country of Origin Concentration (Country_origin_mn)
Our analysis of the country of origin field (country_origin_mn) shows a heavy concentration of registrations in a few manufacturing nations:
| Manufacturer Country (English) | Database Label (Mongolian) | Active Registrations | Percentage of Registry |
|---|---|---|---|
| China | БНХАУ | 410 | 30.4% |
| Japan | Япон | 194 | 14.4% |
| Germany | ХБНГУ | 173 | 12.8% |
| South Korea | БНСУ | 132 | 9.8% |
| France | Франц | 92 | 6.8% |
| Spain | Испани | 78 | 5.8% |
| United States | АНУ | 57 | 4.2% |
| Turkey | БНТУ | 46 | 3.4% |
| Russia | ОХУ | 42 | 3.1% |
| Greece | Грек | 34 | 2.5% |
| Other Countries | Various | 111 | 8.2% |
| Total Register | 1,349 | 100.0% |
Mongolia Diagnostic Register Country Share (Top 4):
China (PRC): [==============================] 410 (30.4%)
Japan: [==============] 194 (14.4%)
Germany: [=============] 173 (12.8%)
South Korea: [==========] 132 (9.8%)
The data shows that China is the dominant exporter of diagnostic products to Mongolia, holding nearly a third of all registrations. This dominance is driven by two main factors: geographical proximity, which reduces logistics costs and shipping times across the Erlian-Zamyn-Uud border, and the competitive pricing of Chinese clinical chemistry and chemiluminescence immunoassay (CLIA) systems.
Combined, China, Japan, and South Korea account for 54.6% of the registry. This strong East Asian presence indicates a highly localized supply chain. Germany and France represent the premium European segment, primarily consisting of high-throughput automated analyzers and specialized molecular reagents. The United States holds a smaller share of 4.2%, reflecting the historical focus of American IVD firms on larger markets.
2. Manufacturer Concentration: Top Players
Who are the specific manufacturers driving these registrations? The 1,349 active products are distributed across 93 unique companies. However, the top 5 manufacturers control 34.3% (463 listings) of the entire register:
| Rank | Manufacturer Name | Country of Origin | Active Listings | Percentage of Registry | Core Product Segment |
|---|---|---|---|---|---|
| 1 | Shenzhen New Industries Biomedical | China | 154 | 11.4% | Chemiluminescence (CLIA) reagents & systems |
| 2 | Biomerieux S.A. | France | 92 | 6.8% | Microbiology, immunoassay, and molecular panels |
| 3 | BioSystems S.A. | Spain | 78 | 5.8% | Clinical chemistry analyzers and reagents |
| 4 | Shenzhen YHLO Biotech Co., Ltd | China | 77 | 5.7% | Autoimmunity and reproductive health assays |
| 5 | Sysmex Corporation | Japan | 62 | 4.6% | Hematology, coagulation, and flow cytometry |
| 6 | Other Manufacturers (88 firms) | Various | 886 | 65.7% | Broad mix of niche IVD developers |
| Total | 1,349 | 100.0% |
The manufacturer list highlights a clear stratification of the Mongolian diagnostic market. Shenzhen New Industries Biomedical Engineering (Snibe) is the absolute leader, holding 11.4% of the register. Snibe's extensive registration profile consists of specialized CLIA test kits (thyroid, cardiac, tumor markers, and infectious diseases) paired with their MAGLUMI analyzer series. Similarly, Shenzhen YHLO Biotech holds 5.7% of the registrations, focusing on autoimmune and reproductive immunology panels.
This indicates that Chinese firms have aggressively registered complete diagnostic menus to capture market share in district-level and provincial hospitals. In contrast, Biomerieux (6.8%) and Sysmex (4.6%) represent the high-end, established Western and Japanese platforms that dominate central laboratories in national hospitals and premium private laboratory chains.
3. Temporal Analysis and the Impending Renewal Wave
By analyzing the registration date stamps embedded in the MMDRA registration numbers (which follow the F[YYYY][MM][DD]Im formatting convention), we can map the annual registration trend:
MMDRA Diagnostic Registrations by Year:
2021: [==============] 141
2022: [==============================] 305
2023: [====================================] 360
2024: [================] 164
The registration volume grew rapidly post-pandemic, peaking in 2023 with 360 new approvals. However, registrations dropped in 2024 to 164, a slowdown directly coinciding with the legislative transition to the new LMMD framework, which caused administrative delays as MMDRA restructured its evaluation panels.
Because Mongolia enforces a strict 5-year validity period for diagnostic registrations, we can project the future certificate expiration wave by analyzing the valid_until date field:
Mongolia Diagnostic Expiry Timeline:
2026: [==============] 139
2027: [==================================================] 496
2028: [=============================================] 451
2029: [======================] 220
2030: [====] 42
This temporal pattern reveals that 947 active diagnostic registrations (70.2% of the register) are scheduled to expire in 2027 and 2028. This concentration represents a major challenge for local importers and a significant risk for foreign manufacturers. If local partners do not initiate the renewal process through LICEMED at least six months prior to expiration, products will face immediate custom clearance delays, resulting in supply chain disruptions.
Step-by-Step Mongolia Registration Workflow
Registering a diagnostic or IVD product in Mongolia under the post-2024 LMMD and MoH Order A/206 rules involves a structured, multi-phase procedure:
The registration process under the new digital framework consists of the following sequential phases:
- Phase 1: Dossier Preparation & translation
- Phase 2: Local Representative (LTR) Appointment
- Phase 3: LICEMED Digital Upload
- Phase 4: MMDRA Completeness Screen
- Phase 5: Scientific Committee Review
- Phase 6: Laboratory Validation & Testing
- Phase 7: Certification & Registry Listing
Phase 1: Dossier Preparation and Translation Compliance
The manufacturer compiles the technical dossier, which must conform to the MMDRA template (closely aligned with the GHTF Common Submission Dossier Template).
- Translation Rules: The instructions for use (IFU), packaging design, and user manual must be translated into Mongolian. The translation must be performed by a certified translation agency and verified by a medical professional. For complex laboratory systems used only by trained pathologists, English IFUs are sometimes accepted, but the outer packaging labels must still feature primary warnings in Mongolian.
- Regulatory Certifications: The dossier must include a valid ISO 13485 certificate, a Free Sale Certificate (FSC) or Certificate of Exportability from the country of origin, and existing marketing approvals (e.g., CE mark, FDA clearance, NMPA approval).
Phase 2: Appointment of a Licensed Local Representative (LTR)
The manufacturer must execute a formal, notarized, and apostilled Power of Attorney appointing a local Mongolian company as their LTR. The LTR must hold a valid Import and Supply License for Medical Devices issued by the Ministry of Health and possess active access to the LICEMED digital portal.
Phase 3: LICEMED Submission
The local representative logs into the LICEMED portal, inputs all manufacturer and product metadata, uploads the electronic PDF files of the dossier, and submits the registration application.
Phase 4: Administrative and Completeness Screening
MMDRA staff perform a desk audit (usually within 10 working days) to verify that all required documents, translations, and certifications have been uploaded. If any deficiencies are identified, the LTR is notified through the portal and has exactly 15 working days to upload the missing documents, or the application will be rejected.
Phase 5: Scientific Committee Evaluation
Once the dossier is complete, it is forwarded to the MMDRA Scientific Committee on Medical Devices. This committee, composed of clinical pathologists, biomedical engineers, and regulatory specialists, meets monthly to review technical documentation, verify performance characteristics (sensitivity, specificity), and evaluate the device's clinical utility for the Mongolian healthcare system.
Phase 6: Laboratory Verification and Testing
For diagnostic reagents and IVD kits, MMDRA may require laboratory validation. The importer must import sample kits (which require a special one-time import permit) and submit them to the National Public Health Institute (NPHI) or a designated national reference laboratory. The laboratory performs verification testing and issues a performance report that is added to the MMDRA dossier.
Phase 7: Approval and Registration
Upon a positive recommendation from the Scientific Committee, the Ministry of Health issues an official state registration certificate with a unique registration number. The product is added to the active Druginfo online registry, allowing the local partner to apply for customs import permits and participate in public procurement tenders.
Comparative Analysis: Central Asia & EAEU Pathways
For global regulatory managers, comparing Mongolia's pathway against its regional neighbors is critical for resource allocation. Below we compare Mongolia (MMDRA) against Kazakhstan (NDDA), Uzbekistan, and the broader Eurasian Economic Union (EAEU) standards:
| Regulatory Feature | Mongolia (MMDRA) | Kazakhstan (NDDA) | Uzbekistan (MOH) | EAEU Unified Pathway |
|---|---|---|---|---|
| Primary Regulator | MMDRA / Ministry of Health | National Center for Expertise (NDDA) | Main Directorate of Quality Control | Eurasian Economic Commission |
| Applicable Law | LMMD (Revised 2024) | Code on Health of the Nation | Law on Medicines & Devices | EAEU Treaty & Agreements |
| Filing System | Digital (LICEMED) | Digital (NDDA Portal) | Semi-digital | Digital (EEC Portal) |
| CE Reliance | High (CE mark heavily streamlines technical review) | Moderate (EAEU registration requires local clinical trials) | High (reliance on EU/FDA marketing history) | Low (requires full EAEU dossier compliance) |
| Validity Period | 5 Years | 5 Years (or perpetual for specific items) | 5 Years | 5 Years (first, then perpetual) |
| Local Testing | Yes (required for IVD/reagents validation) | Yes (local clinical & technical trials required) | Yes (clinical testing in national institutes) | Yes (local trials in accredited EAEU labs) |
| EAC Regional Integration | Standalone market | Member of EAEU | CIS observer, standalone | Unified EAEU market access |
Mongolia's standalone system represents a simpler, more direct route than the EAEU pathway. While Kazakhstan's NDDA registry is much larger—as analyzed in our Kazakhstan NDDA medical device registry teardown—the transition to the unified EAEU pathway requires expensive local clinical trials and technical testing in EAEU-accredited laboratories.
In contrast, Mongolia's new MMDRA system, while modernized, retains a high degree of reliance on European CE marking and NMPA/FDA approvals, allowing desk-based reviews supplemented by local laboratory validation for IVDs. This makes Mongolia a cost-effective expansion target for firms that have already registered their portfolios in China or Europe, especially when coordinating a broader Asia-Pacific medical device registration strategy.
Strategic Market Entry and Channel Management Recommendations
To succeed in Mongolia's diagnostic market, foreign manufacturers should implement the following channel strategies:
1. Mitigate LTR Lock-In Risk
Under the LMMD framework, the state registration certificate is registered in the name of the local importer (the holder of the Import and Supply License). This creates a standard "lock-in" risk: if the distributor performs poorly, the manufacturer cannot easily transfer the registration to a new partner.
- Contractual Protections: Foreign manufacturers must mandate that the distribution agreement contains a clause requiring the LTR to provide a pre-signed, undated, and irrevocable "Letter of No Objection" to transfer the MMDRA registration upon contract termination.
- Dual Registration: Because MMDRA permits the same product to be registered by different importers (provided they submit separate dossiers and pay separate fees), manufacturers of high-volume products can register through multiple distributors to maintain channel competition.
2. Reagent-to-Hardware Supply Agreements
Because the register shows that China dominates reagent supply, competing on price for generic reagents is difficult. Manufacturers of premium platforms should secure their reagent volume by leasing hardware to key private clinics and national hospitals under strict minimum reagent consumption contracts. Ensuring that the hardware is registered alongside the reagent menu under a unified LICEMED application prevents competitors from supplying third-party reagents to the leased system.
3. Plan Ahead for the 2027–2028 Expiration Wave
With over 70% of the active register set to expire in 2027 and 2028, manufacturers must audit their Mongolian portfolios immediately. Local partners should be required to submit renewal dossiers via LICEMED at least six months prior to expiration. Failure to do so will lead to automatic customs clearance blocks, allowing competitors to capture public tender slots.
Frequently Asked Questions (FAQs)
Do all medical devices need to be registered in Mongolia under the new 2024 LMMD?
Yes. The revised Law on Medicines and Medical Devices (LMMD), which entered into force on October 1, 2024, mandates that all medical devices—including laboratory diagnostic equipment, clinical consumables, and in vitro diagnostics—must hold a valid state registration or marketing authorization before importation and sale.
Can a foreign medical device manufacturer hold the MMDRA registration directly?
No. MMDRA registration certificates can only be issued to Mongolian legal entities that hold a valid Import and Supply License for Medical Devices issued by the Ministry of Health. Foreign manufacturers must appoint a licensed local importer to act as their Authorized Representative.
What is the LICEMED system, and how is it used?
LICEMED (licemed.mohs.mn) is the online database and application portal managed by the MMDRA. Local representatives use the portal to submit registration dossiers, apply for import clearance permits, pay evaluation fees, and track the status of scientific committee reviews.
What are the official registration fees and validity periods in Mongolia?
Standard MMDRA registration certificates are valid for 5 years. Administrative registration fees range from 500,000 to 3,000,000 MNT (approx. $150 to $900 USD) for a new registration, and 250,000 to 1,500,000 MNT (approx. $75 to $450 USD) for renewals.
References
- Law of Mongolia on Medicines and Medical Devices (Revised Edition), State Great Khural, June 5, 2024 (Effective October 1, 2024). Legalinfo.mn portal.
- Minister of Health Order No. A/206, "Procedure for the Registration and Marketing Authorization of Medical Devices," Ministry of Health of Mongolia, May 26, 2025.
- MMDRA Registered Diagnostic Products Database (Druginfo), Authority for Health and Medical Device Regulation, Ministry of Health of Mongolia, July 2026. Official Portal.
- PwC Mongolia Legal Alert No. 05/2025, "New Procedures for Medical Device Registration and Marketing Authorization," PricewaterhouseCoopers Tax & Legal Advisory LLP, June 2025.
- Balkans & CIS MedTech Access Guide, OMC Medical Regulatory Consulting, 2025.
- Mongolia Health Sector Development Program Report, World Health Organization (WHO) Regional Office for the Western Pacific, 2024.